23.10.2012 • News

Lonza, OncoMed to Collaborate on Anti-Cancer Therapeutics

Lonza and OncoMed Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to improving cancer treatment, announced today an agreement for the development and manufacture of OncoMed's pipeline of anti-cancer stem cell therapeutics.

Under the agreement, Lonza will produce material at its mammalian manufacturing facility in Slough, UK. The multi-product GS SystemLicense provides access to Lonza's GS Gene Expression System and Version 8 Media and Feeds Manufacturing Platform.

OncoMed's pipeline is focused on the development of novel monoclonal antibodies that target cancer stem cells.

 

Interview

Driving Transformation
Interconnected Global Chemicals Logistics

Driving Transformation

DP World is reshaping global chemical supply chains. Christene Smith of CHEManager interviews Markus Kanis, Global SVP Chemicals, on the company’s roadmap, new technologies, and the evolving demands of global trade.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Top-Feature

most read